drugset / Trial / NCT01464164

Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia

NCT01464164

Phase 1/2 Terminated 19 enrolled Northwell Health
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and dosing of drug Sotatercept, as a subcutaneous injection, to stimulate production of red blood cell production. To be given every 28 days for up to four doses.

Timeline

Start
2012-01
Primary completion
2021-04-13
Completion
2021-04-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisone Other / unclassified 1 mg/kg
Subject Sotatercept Protein / enzyme biologic 0.05 mg/kg Subcutaneous
Subject Sotatercept Protein / enzyme biologic 0.075 mg/kg Subcutaneous
Subject Sotatercept Protein / enzyme biologic 0.1 mg/kg Subcutaneous
Subject Sotatercept Protein / enzyme biologic 0.3 mg/kg Subcutaneous
Subject Sotatercept Protein / enzyme biologic 0.75 mg/kg Subcutaneous
Subject Sotatercept Protein / enzyme biologic 1 mg/kg Subcutaneous